Poland· PL-100374200
Cinqaero
A reslizumab product containing reslizumabum, registered in Poland by Teva B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Reslizumabum
- Manufacturer
- Teva B.V.
- Country
- Poland (PL)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991286200
- gtin05909991326081
- gtin05909991360276
- gtin05909991360283
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- FinlandCINQAEROTeva B.V.
- BelgiumCinqaero 10 mg/mlTeva
- United StatesCINQAIRTeva Respiratory, LLC
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
- IcelandCinqaeroTeva B.V.*
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0856f063-36e9-4052-b22d-d6d590394798 GET /v1/drugs/0856f063-36e9-4052-b22d-d6d590394798?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mg/ml",
"packaging": "05909991286200 ¦ Rpz ¦ EU/1/16/1125/001 ¦ 116870\n1 fiol. 10 ml\n05909991326081 ¦ Rpz ¦ EU/1/16/1125/002 ¦ 121595\n1 fiol. 2,5 ml\n05909991360276 ¦ Rpz ¦ EU/1/16/1125/003 ¦ 126445\n2 fiol. 10 ml\n05909991360283 ¦ Rpz ¦ EU/1/16/1125/004 ¦ 126446\n2 fiol. 2,5 ml",
"substance": "Reslizumabum 10 mg/ml",
"common_name": "Reslizumabum",
"pl_product_id": "100374200",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.